Literature DB >> 32594397

Molecular Ultrasound Imaging.

Jasmin Baier1, Anne Rix1, Fabian Kiessling2.   

Abstract

Contrast-enhanced ultrasound (CEUS) imaging is a valuable tool for preclinical and clinical diagnostics. The most frequently used ultrasound contrast agents are microbubbles. Besides them, novel nano-sized materials are under investigation, which are briefly discussed in this chapter. For molecular CEUS, the ultrasound contrast agents are modified to actively target disease-associated molecular markers with a site-specific ligand. The most common markers for tumor imaging are related to neoangiogenesis, like the vascular endothelial growth factor receptor-2 (VEGFR2) and αvβ3 integrin. In this chapter, applications of molecular ultrasound to longitudinally monitor receptor expression during tumor growth, to detect neovascularization, and to evaluate therapy responses are described. Furthermore, we report on first clinical trials of molecular CEUS with VEGFR2-targeted phospholipid microbubbles showing promising results regarding patient safety and its ability to detect tumors of prostate, breast, and ovary. The chapter closes with an outlook on ultrasound theranostics, where (targeted) ultrasound contrast agents are used to increase the permeability of tumor tissues and to support drug delivery.

Entities:  

Keywords:  Active targeting; BR55; CEUS; Imaging; Integrin; Microbubble; Ultrasound imaging; VEGFR2

Mesh:

Substances:

Year:  2020        PMID: 32594397     DOI: 10.1007/978-3-030-42618-7_15

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  2 in total

Review 1.  Alternatives for MRI in Prostate Cancer Diagnostics-Review of Current Ultrasound-Based Techniques.

Authors:  Adam Gurwin; Kamil Kowalczyk; Klaudia Knecht-Gurwin; Paweł Stelmach; Łukasz Nowak; Wojciech Krajewski; Tomasz Szydełko; Bartosz Małkiewicz
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.575

2.  Evaluation of efficacy of ultrasound-guided microwave ablation in primary hyperparathyroidism.

Authors:  Mingzhu Zhang; Yuxiu Gao; Xiaojuan Zhang; Zhaoyan Ding; Xinya Wang; Wenbin Jiang; Cheng Zhao
Journal:  J Clin Ultrasound       Date:  2022-01-05       Impact factor: 0.869

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.